NCT03244306View on ClinicalTrials.gov

A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 27, 2017

Primary Completion Date

November 14, 2018

Study Completion Date

July 31, 2035

Conditions
Leukemia
Interventions
BIOLOGICAL

Patient-derived CD22-specific CAR T-cells also expressing an EGFRt

Patient-derived CD22-specific chimeric antigen receptor T-cells expressing an EGFRt

Trial Locations (1)

98105

Seattle Children's Hospital, Seattle

All Listed Sponsors
lead

Seattle Children's Hospital

OTHER